Rhythm Pharmaceuticals (RYTM) Invested Capital (2016 - 2025)
Rhythm Pharmaceuticals (RYTM) has disclosed Invested Capital for 10 consecutive years, with $146.4 million as the latest value for Q4 2025.
- On a quarterly basis, Invested Capital rose 528.99% to $146.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $146.4 million, a 528.99% increase, with the full-year FY2025 number at $146.4 million, up 528.99% from a year prior.
- Invested Capital was $146.4 million for Q4 2025 at Rhythm Pharmaceuticals, down from $154.4 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $380.9 million in Q1 2021 to a low of -$8.1 million in Q2 2025.
- A 5-year average of $182.0 million and a median of $189.9 million in 2023 define the central range for Invested Capital.
- Biggest YoY gain for Invested Capital was 1276.49% in 2025; the steepest drop was 120.66% in 2025.
- Rhythm Pharmaceuticals' Invested Capital stood at $284.2 million in 2021, then decreased by 7.0% to $264.3 million in 2022, then plummeted by 35.76% to $169.8 million in 2023, then crashed by 86.29% to $23.3 million in 2024, then soared by 528.99% to $146.4 million in 2025.
- Per Business Quant, the three most recent readings for RYTM's Invested Capital are $146.4 million (Q4 2025), $154.4 million (Q3 2025), and -$8.1 million (Q2 2025).